(Rewrites para 1, adds details on H1 FY23 in paragraph 3, FY24 profit forecast in paragraph 4)
June 14 (Reuters) - Australian biotech giant CSL Ltd (CSL) said on Wednesday its constant-currency profit for fiscal year 2023 is expected to be at the top end of its guidance range of $2.7 billion to $2.8 billion.
The company also said it now sees a foreign currency impact of between $230 million and $250 million for FY23, up from a previous forecast of $175 million.
CSL had posted underlying profit, excluding one-off items, of $1.96 billion on a constant-currency basis for the half year, up 10% from a year earlier, due to a resurgence in blood plasma donations which enabled it to boost sales.
The firm also expects its FY24 net profit after tax and amortisation to rise about 13% to 18% to between $2.9 billion and $3.0 billion at constant currency.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$263.95 |
Change
8.640(3.38%) |
Mkt cap ! $127.8B | |||
| Open | High | Low | Value | Volume |
| $258.12 | $264.81 | $257.91 | $311.0M | 1.182M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 833 | $263.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $263.98 | 30529 | 2 |
View Market Depth
| Last trade - 16.10pm 22/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |